Lyra Therapeutics Inc Share Price Today: Live Updates & Key Insights

Lyra Therapeutics Inc share price today is $0.3572, up -62.5%. The stock opened at $1.25 against the previous close of $1.32, with an intraday high of $1.25 and low of $0.4847.

Lyra Therapeutics Inc Share Price Chart

Lyra Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Lyra Therapeutics Inc Share Price Performance

$0.3572 -0.625(-62.5%) LYRA at 23 Mar 2026 02:11 PM Biotechnology
Lowest Today 0.4847
Highest Today 1.25
Today’s Open 1.25
Prev. Close 1.32
52 Week High 34.00
52 Week Low 0.48
Day’s Range: Low 0.4847 High 1.25
52-Week Range: Low 0.48 High 34.00
1 day return -
1 Week return -
1 month return -66.09
3 month return -86.43
6 month return -92.39
1 year return +203.86
3 year return -76.31
5 year return -96.36
10 year return -

Lyra Therapeutics Inc Institutional Holdings

Perceptive Advisors LLC 12.92

Sabby Management LLC 9.87

Ikarian Capital, LLC 1.19

Geode Capital Management, LLC 0.69

Artia Global Partners LP 0.49

Fidelity Extended Market Index 0.37

Vanguard Institutional Extnd Mkt Idx Tr 0.35

UBS Group AG 0.23

Tower Research Capital LLC 0.12

BlackRock Inc 0.10

Spartan Total Market Index Pool G 0.09

Blackrock Extended Mkt Fund CF 0.09

Extended Equity Market Fund K 0.08

Royal Bank of Canada 0.07

Morgan Stanley - Brokerage Accounts 0.07

Fidelity Series Total Market Index 0.07

Fidelity Total Market Index 0.07

Citigroup Inc 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

EverSource Wealth Advisors, LLC 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

JONES FINANCIAL COMPANIES LLLP 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Extended Equity Market Fund M 0.01

SSgA U.S. Total Market Index Strategy 0.00

SBI Securities Co Ltd 0.00

JPMorgan Chase & Co 0.00

BNYM Mellon SL Market Completion UC1 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

NT US Market Cap Idx Fd - L 0.00

CWM, LLC duplicate 0.00

Comerica Bank 0.00

Advisor Group Holdings, Inc. 0.00

Bryn Mawr Trust Company 0.00

Bank of America Corp 0.00

Lyra Therapeutics Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 4

Sell: 0

Strong Sell: 0

Lyra Therapeutics Inc Fundamentals

Market Cap 2.34 M

PB Ratio 3.9033

PE Ratio 0.0

Enterprise Value 11.67 M

Total Assets 66.35 M

Volume 1396144

Lyra Therapeutics Inc Company Financials

Annual Revenue FY23:1423000 1.4M, FY22:1363000 1.4M, FY21:285000 0.3M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:1363000 1.4M, FY21:285000 0.3M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-61759000 -61.8M, FY22:-55278000 -55.3M, FY21:-42410000 -42.4M, FY20:-22045000 -22.0M, FY19:-16093000 -16.1M

Quarterly Revenue Q3/2025:25000 0.0M, Q2/2025:183000 0.2M, Q1/2025:183000 0.2M, Q3/2024:195000 0.2M, Q2/2024:598000 0.6M

Quarterly Profit Q3/2025:-75000 -0.1M, Q2/2025:-17000 -0.0M, Q1/2025:183000 0.2M, Q3/2024:195000 0.2M, Q2/2024:-12666000 -12.7M

Quarterly Net worth Q3/2025:-5984000 -6.0M, Q2/2025:-7437000 -7.4M, Q1/2025:-8547000 -8.5M, Q3/2024:-11873000 -11.9M, Q2/2024:-48131000 -48.1M

About Lyra Therapeutics Inc & investment objective

Company Information Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 30

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Lyra Therapeutics Inc FAQs

What is the share price of Lyra Therapeutics Inc today?

The current share price of Lyra Therapeutics Inc is $0.3572.

Can I buy Lyra Therapeutics Inc shares in India?

Yes, Indian investors can buy Lyra Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Lyra Therapeutics Inc shares in India?

You can easily invest in Lyra Therapeutics Inc shares from India by:

Can I buy fractional shares of Lyra Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Lyra Therapeutics Inc?

Lyra Therapeutics Inc has a market cap of $2.34 M.

In which sector does Lyra Therapeutics Inc belong?

Lyra Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Lyra Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Lyra Therapeutics Inc?

The PE ratio of Lyra Therapeutics Inc is N/A and the PB ratio is 3.90.